Дело C-220/21: ratiopharm и др./Orion и Комисия, Определение от 24 юни 2021 г.

Текст

... blic health – Medicinal products for human use – Regulation (EC) No 726/2004 – Directive 2001/83/EC – Decision granting marketing authorisation for the medicinal product for human use Dexmedetomidine Accord – dexmedetomidine – Dismissal)

In Case C‑220/21 P(I),

APPEAL under the first paragraph of Article 57 of the Statute of the Court of Justice of the European Union, brought on 6 April 2021,

ratiopharm GmbH, established in Ulm (Germany),

Teva Pharma – Produtos Farmaceuticos Lda, established in Porto Salvo (Portugal),

Teva Danmark A/S, established in Søborg (Denmark),

Teva Sweden AB, established in Stockholm (Sweden),

Teva Nederland BV, established in Haarlem (Netherlands),

represented by O. Swens, advocaat,

appellants,

the other parties to the proceedings being:

Orion Oyj, established in Espoo (Finland), represented by C. Schoonderbeek, advocaat, and by J. Mulryne and E. Amos, Solicitors,

applicant at first instance,

European Commission, represented by L. Haasbeek and R. Lindenthal, acting as Agents,

defendant at first instance,

THE VICE-PRESIDENT OF THE COURT,

after hearing the Advocate General, M. Szpunar,

makes the following

Order

1. By their appeal, ratiopharm GmbH, Teva Pharma – Produtos Farmaceuticos Lda, Teva Danmark A/S, Teva Sweden AB and Teva Nederland BV (‘Teva and Others’) seek a declaration from the Court of Justice that an error in law was made by the President of the Eighth Chamber of the General Court of the European Union in his order of 5 March 2021, Orion v Commission (T‑223/20, not published, EU:T:2021:137; ‘the order under appeal’), by which the latter dismissed their application to ...